Development of a lymphocytic lymphoma during immunosuppressive therapy with azathioprine for systemic lupus erythematosus with renal involvement induced by phenylbutazone.
A case of systemic lupus erythematosis (SLE) with renal involvement after the administration of phenylbutazone is described. The patient subsequently developed a lymphocytic lymphoma following two years treatment with azathioprine and prednisone. Although the association between SLE, immunosuppressive therapy and the development of lymphomas is well documented, the increased incidence of malignant disease in uremic patients is less well recognized. The varied factors that may have contributed to the development of the lymphoma in this case are discussed, together with a review of the literature.
D001379:Azathioprine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000150:complications*; D010653:Phenylbutazone / Q000009:adverse effects* / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use
D010653:Phenylbutazone; D001379:Azathioprine; D011241:Prednisone